Photo: ROBERT SULLIVAN / AFP / Getty Images
Doctors have discovered that clopidogrel, a commonly prescribed blood thinner, is more effective than aspirin in preventing heart attacks and strokes. This groundbreaking finding was presented at the European Society of Cardiology congress in Madrid and published in the Lancet medical journal. The study involved an international team of scientists from the U.S., UK, Australia, Switzerland, and Japan, who analyzed data from nearly 29,000 patients with coronary artery disease (CAD).
The research revealed that clopidogrel reduced the risk of major cardiovascular events by 14% compared to aspirin, without increasing the risk of major bleeding. This challenges the longstanding recommendation of aspirin as the default treatment for preventing serious cardiovascular events in CAD patients. CAD, the most common form of heart disease, affects over 300 million people worldwide.
The study's authors emphasized that clopidogrel should become the preferred long-term antiplatelet treatment for CAD patients due to its superior efficacy and similar safety profile to aspirin. The widespread availability and affordability of clopidogrel further support its potential for extensive adoption in clinical practice.
The Guardian reported that the findings could transform health guidelines worldwide, impacting the medications doctors prescribe to reduce the risk of future heart problems. Further research on the cost-effectiveness of clopidogrel and broader population studies will be needed to support changes in treatment standards.
According to the BMJ, the study's comprehensive analysis included diverse patient groups and various subgroups, ensuring the generalizability of the findings. Despite potential genetic or clinical factors affecting clopidogrel responsiveness, patients still benefited more from clopidogrel than aspirin.
This discovery could significantly impact global health guidelines, potentially leading to the widespread adoption of clopidogrel as the preferred treatment for preventing heart attacks and strokes in CAD patients.